Eli Lilly and Company: Lymphoma trials
The registry lists 12 Lymphoma studies with Eli Lilly and Company as lead sponsor. 0 are open to participants now and 8 have results posted.
Phase 1 9Phase 2 1Phase 3 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)Active, not recruitingNCT04666038Phase 3Results posted
- A Study of LY2835219 in Japanese Participants With Advanced CancerCompletedNCT02014129Phase 1Results posted
- A Study of LY3039478 in Participants With Advanced CancerCompletedNCT01695005Phase 1Results posted
- A Study of Enzastaurin in Chinese Patients With Advanced and/or Metastatic Solid Tumors or LymphomaCompletedNCT01432951Phase 1Results posted
- A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of WarfarinCompletedNCT01388335Phase 1Results posted
- A Tasisulam and Midazolam Drug Interaction Study in Cancer PatientsTerminatedNCT01209832Phase 1Results posted
- A Drug Interaction Study of Tasisulam in Patients With Advanced Cancer or LymphomaTerminatedNCT01185548Phase 1Results posted
- A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP OnlyCompletedNCT00451178Phase 2Results posted
- Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)Active, not recruitingNCT04662255Phase 3
- A Study of LY3023414 in Participants With Advanced CancerCompletedNCT01655225Phase 1
- A Study of LY2875358 in Japanese Participants With Advanced CancerCompletedNCT01602289Phase 1
- Study of IMC-3G3 in Patients With Tumors That Are Not Responding to Standard Therapies or No Therapy is AvailableCompletedNCT00768391Phase 1